Benign Prostatic Hyperplasia Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Benign Prostatic Hyperplasia pipeline constitutes 10+ key companies continuously working towards developing 10+ Benign Prostatic Hyperplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Benign Prostatic Hyperplasia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Benign Prostatic Hyperplasia Market.

The Benign Prostatic Hyperplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Benign Prostatic Hyperplasia Pipeline Report: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Benign Prostatic Hyperplasia treatment therapies with a considerable amount of success over the years.
• Benign Prostatic Hyperplasia companies working in the treatment market are AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others, are developing therapies for the Benign Prostatic Hyperplasia treatment
• Emerging Benign Prostatic Hyperplasia therapies in the different phases of clinical trials are- AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others are expected to have a significant impact on the Benign Prostatic Hyperplasia market in the coming years.
• In March 2026, Prodeon Medical has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Urocross Expander System, a temporary implant technology designed to treat lower urinary tract symptoms (LUTS) linked to benign prostatic hyperplasia (BPH).
• In January 2026, Butterfly Medical, a company developing a proprietary non-surgical treatment for benign prostatic hyperplasia (BPH), has announced the successful completion of the final 12-month follow-up for all participants in its international pivotal clinical trial. This landmark study aims to assess the safety and effectiveness of the Butterfly Prostatic Retraction Device, a first-line interventional therapy (FIT) for BPH.
• In December 2025, Zenflow, Inc. announced that the FDA has approved its Zenflow Spring Implant and Delivery System for the treatment of symptoms related to benign prostatic hyperplasia (BPH). This first-line interventional therapy is designed to widen the urethra while maintaining natural anatomy through a proprietary spring-like implant. The company also highlighted that this is the first FDA-approved BPH treatment performed in an outpatient setting using the Zenflow Spring Scope, which received FDA 510(k) clearance earlier this year.
• In April 2025, The investigational ProVee Urethral Expander System for benign prostatic hyperplasia (BPH) met all safety and effectiveness endpoints in a Phase 3 study, as reported at the 2025 American Urological Association Annual Meeting. Steven A. Kaplan, MD, presented data from the ProVIDE trial (NCT05186740), a Phase 3, prospective, multicenter, randomized, double-blind, sham-controlled study assessing the safety, performance, and effectiveness of ProVee. Patients were randomly assigned in a 2:1 ratio to receive either ProVee or a sham procedure (simulated delivery with no stent deployed). The study included men aged 45 and older with moderate-to-severe symptomatic BPH, an International Prostate Symptom Score (IPSS) of at least 13, and an IPSS V/S of at least 1 at baseline.
• In October 2024, EDAP TMS SA announced that the first patients have been treated in a Phase 1/2 study (NCT06601179) assessing the safety and effectiveness of Focal One robotic high-intensity focused ultrasound (HIFU) for the treatment of benign prostatic hyperplasia (BPH).

Benign Prostatic Hyperplasia Overview
Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a common condition that affects older men. The prostate gland, which is part of the male reproductive system, surrounds the urethra (the tube that carries urine from the bladder out of the body).

Get a Free Sample PDF Report to know more about Benign Prostatic Hyperplasia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Benign Prostatic Hyperplasia Drugs Under Different Phases of Clinical Development Include:
• AIV007: AiViva BioPharma
• CKD-846: Chong Kun Dang
• DTT106: EMS
• Paclitaxel: Urotronic Inc.
• RT-310: Resurge Therapeutics Inc
• Teverelix trifluoroacetate Antev
• Fexapotide: Nymox Pharmaceutical
• GI198745: GlaxoSmithKline
• DKF-313: Dongkook Pharmaceutical
• Silodosin: RECORDATI GROUP
• ASP4901: Astellas Pharma Inc
• Tadalafil: Eli Lilly and Company
• PRX302: Sophiris Bio Corp
• Levitra (Vardenafil, BAY38-9456): Bayer
• PRX302: Sophiris Bio Corp
• WC3055: Warner Chilcott
• NX-1207: Nymox Corporation
• QLT0074: QLT Inc.
• Tamsulosin Hydrochloride: NeoTract, Inc.
• Ningmitai capsule: Xintian Pharmaceutical

Benign Prostatic Hyperplasia Route of Administration
Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Benign Prostatic Hyperplasia Molecule Type
Benign Prostatic Hyperplasia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Benign Prostatic Hyperplasia Pipeline Therapeutics Assessment
• Benign Prostatic Hyperplasia Assessment by Product Type
• Benign Prostatic Hyperplasia By Stage and Product Type
• Benign Prostatic Hyperplasia Assessment by Route of Administration
• Benign Prostatic Hyperplasia By Stage and Route of Administration
• Benign Prostatic Hyperplasia Assessment by Molecule Type
• Benign Prostatic Hyperplasia by Stage and Molecule Type

DelveInsight's Benign Prostatic Hyperplasia Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Benign Prostatic Hyperplasia product details are provided in the report. Download the Benign Prostatic Hyperplasia pipeline report to learn more about the emerging Benign Prostatic Hyperplasia therapies
https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Benign Prostatic Hyperplasia Therapeutics Market include:
Key companies developing therapies for Benign Prostatic Hyperplasia are - Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC, Astellas Pharma Inc., and others.

Benign Prostatic Hyperplasia Pipeline Analysis:
The Benign Prostatic Hyperplasia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Benign Prostatic Hyperplasia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Benign Prostatic Hyperplasia Treatment.
• Benign Prostatic Hyperplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Benign Prostatic Hyperplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Benign Prostatic Hyperplasia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Benign Prostatic Hyperplasia drugs and therapies
https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Benign Prostatic Hyperplasia Pipeline Market Drivers
• The prevalence of this disease drives demand for treatments, creating a growth opportunity for pharmaceutical companies and medical device manufacturers in the BPH market thus fuels research, development, and innovation, leading to the introduction of new therapies and technologies.

Benign Prostatic Hyperplasia Pipeline Market Barriers
• The presence of significant side effects linked to BPH treatments can deter patient adherence and acceptance, limiting market expansion as concerns about safety and tolerability affect physician prescribing patterns and hinder uptake of therapies

Scope of Benign Prostatic Hyperplasia Pipeline Drug Insight
• Coverage: Global
• Key Benign Prostatic Hyperplasia Companies: AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others
• Key Benign Prostatic Hyperplasia Therapies: AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others
• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.